Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma ; volume:92 ; number:4 ; day:26 ; month:7 ; year:2023 ; pages:303-314 ; date:10.2023
Cancer chemotherapy and pharmacology ; 92, Heft 4 (26.7.2023), 303-314, 10.2023
- Creator
-
Nishi, Hidemi
Gotoh, Kunihito
Tomimaru, Yoshito
Kobayashi, Shogo
Sasaki, Kazuki
Iwagami, Yoshifumi
Yamada, Daisaku
Akita, Hirofumi
Asaoka, Tadafumi
Noda, Takehiro
Takahashi, Hidenori
Tanemura, Masahiro
Doki, Yuichiro
Eguchi, Hidetoshi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00280-023-04531-w
- URN
-
urn:nbn:de:101:1-2023110414023686236564
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nishi, Hidemi
- Gotoh, Kunihito
- Tomimaru, Yoshito
- Kobayashi, Shogo
- Sasaki, Kazuki
- Iwagami, Yoshifumi
- Yamada, Daisaku
- Akita, Hirofumi
- Asaoka, Tadafumi
- Noda, Takehiro
- Takahashi, Hidenori
- Tanemura, Masahiro
- Doki, Yuichiro
- Eguchi, Hidetoshi
- SpringerLink (Online service)
Other Objects (12)
Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
A case of adenocarcinoma arising in an ileal diverticulum resected by laparoscopic surgery
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)
MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
COL8A1 promotes progression and gemcitabine resistance of pancreatic ductal adenocarcinoma through an autocrine/paracrine fashion
MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma
N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance
Thoracoscopic and endoscopic cooperative surgery (TECS): a novel less invasive technique for resection of gastric tube cancer after esophagectomy
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
A case of adenocarcinoma arising in an ileal diverticulum resected by laparoscopic surgery
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)
MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
COL8A1 promotes progression and gemcitabine resistance of pancreatic ductal adenocarcinoma through an autocrine/paracrine fashion
MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma
N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance
Thoracoscopic and endoscopic cooperative surgery (TECS): a novel less invasive technique for resection of gastric tube cancer after esophagectomy
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
A case of adenocarcinoma arising in an ileal diverticulum resected by laparoscopic surgery
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)
MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
COL8A1 promotes progression and gemcitabine resistance of pancreatic ductal adenocarcinoma through an autocrine/paracrine fashion
MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma
N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance
Thoracoscopic and endoscopic cooperative surgery (TECS): a novel less invasive technique for resection of gastric tube cancer after esophagectomy
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma